Unveiling therapeutic potentials and exploring maternal-fetal health benefits of metformin in pregnancy: A scoping review.
fetal outcomes
gestational diabetes
maternal outcomes
obesity
polycystic ovary syndrome
type 2 diabetes
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
revised:
20
05
2024
received:
12
01
2024
accepted:
01
06
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
This scoping review synthesizes evidence on metformin's use during pregnancy, encompassing diverse conditions like gestational diabetes, type 1 and type 2 diabetes, polycystic ovary syndrome (PCOS), and obesity. Metformin demonstrates comparable efficacy to insulin in gestational diabetes, positive outcomes in type 2 diabetes pregnancies, and potential benefits in reducing complications. The review highlights nuances in its effects across conditions, indicating advantages such as reduced risk of macrosomia and cesarean section in gestational diabetes. However, its prophylactic role in preventing gestational diabetes and associated complications remains inconclusive. In obese pregnant women, mixed results are observed, with potential benefits in reducing pre-eclampsia risk. Metformin shows promise in preventing preterm birth and late miscarriage in PCOS pregnancies. Categorizing patient subgroups is crucial for identifying advantages, especially in gestational diabetes and type 2 diabetes. Challenges arise from study heterogeneity, necessitating standardized indications for dosage, timing, and postpartum follow ups. Efforts to identify patient characteristics influencing metformin efficacy are crucial for tailored therapy. Although metformin emerges as a viable option in complicated pregnancies, comprehensive research, standardized protocols, and subgroup identification efforts will enhance clinical utility, ensuring evidence-based therapies and optimal maternal and fetal outcomes. Bridging existing knowledge gaps remains imperative for advancing metformin's role in pregnancy management.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 International Federation of Gynecology and Obstetrics.
Références
Caughey AB, Turrentine M. ACOG practice bulletin no. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):E49‐E64. doi:10.1097/AOG.0000000000002501
Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos. 2010;38(5):833. doi:10.1124/DMD.109.031245
ElSayed N, Aleppo G, Aroda VR, et al. 15. Management of Diabetes in pregnancy: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S254‐S266. doi:10.2337/DC23-S015
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA‐ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467‐473. doi:10.7326/M18-0850
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003‐2015. doi:10.1056/NEJMOA0707193
Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Francisco RPV. Randomized trial of metformin vs insulin in the management of gestational diabetes. Am J Obstet Gynecol. 2013;209(1):34.e1‐34.e7. doi:10.1016/J.AJOG.2013.03.022
Picón‐César MJ, Molina‐Vega M, Suárez‐Arana M, et al. Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial. Am J Obstet Gynecol. 2021;225(5):517.e1‐517.e17. doi:10.1016/J.AJOG.2021.04.229
Bao LX, Shi WT, Han YX. Metformin versus insulin for gestational diabetes: a systematic review and meta‐analysis. J Matern Fetal Neonatal Med. 2021;34(16):2741‐2753. doi:10.1080/14767058.2019.1670804
Valdés E, Sepúlveda‐Martínez A, Candia P, et al. Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: a randomized study. J Obstet Gynaecol Res. 2018;44(1):81‐86. doi:10.1111/JOG.13477
Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834‐844. doi:10.1016/S2213-8587(20)30310-7
Chiswick C, Reynolds RM, Denison F, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):778‐786. doi:10.1016/S2213-8587(15)00219-3
Dodd JM, Louise J, Deussen AR, et al. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2019;7(1):15‐24. doi:10.1016/S2213-8587(18)30310-3
Do Nascimento IB, Sales WB, Dienstmann G, de Souza MLR, Fleig R, Silva JC. Metformin for prevention of cesarean delivery and large‐for‐gestational‐age newborns in non‐diabetic obese pregnant women: a randomized clinical trial. Arch Endocrinol Metab. 2020;64(3):290‐297. doi:10.20945/2359-3997000000251
Dienstmann G, Nascimento IB, Sales WB, et al. No effect of a low dose of metformin on the lipid profile, body mass index and weight gain in pregnant women with obesity: a randomized trial. Obes Res Clin Pract. 2020;14(6):561‐565. doi:10.1016/J.ORCP.2020.09.005
Zeng XL, Zhang YF, Tian Q, Xue Y, An RF. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta‐analysis. Medicine (Baltimore). 2016;95(36):e4526. doi:10.1097/MD.0000000000004526
Zhao J, Liu X, Zhang W. The effect of metformin therapy for preventing gestational diabetes mellitus in women with polycystic ovary syndrome: a meta‐analysis. Exp Clin Endocrinol Diabetes. 2020;128(3):199‐205. doi:10.1055/A-0603-3394
Vanky E, Salvesen KÅ, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19(8):1734‐1740. doi:10.1093/HUMREP/DEH347
Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448‐E455. doi:10.1210/JC.2010-0853
Løvvik TS, Carlsen SM, Salvesen Ø, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2019;7(4):256‐266. doi:10.1016/S2213-8587(19)30002-6
Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12(12):CD006105. doi:10.1002/14651858.CD006105.PUB4
Wu Y, Tu M, Huang Y, Liu Y, Zhang D. Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization: a systematic review and meta‐analysis. JAMA Netw Open. 2020;3(8):e2011995. doi:10.1001/JAMANETWORKOPEN.2020.11995
Brand KMG, Saarelainen L, Sonajalg J, et al. Metformin in pregnancy and risk of adverse long‐term outcomes: a register‐based cohort study. BMJ Open Diabetes Res Care. 2022;10(1):e002363. doi:10.1136/BMJDRC-2021-002363
Paavilainen E, Tertti K, Nikkinen H, et al. Metformin versus insulin therapy for gestational diabetes: effects on offspring anthropometrics and metabolism at the age of 9 years: a follow‐up study of two open‐label, randomized controlled trials. Diabetes Obes Metab. 2022;24(3):402‐410. doi:10.1111/DOM.14589
Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow‐up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res Care. 2018;6(1):e000456. doi:10.1136/BMJDRC-2017-000456
Hanem LGE, Salvesen Ø, Juliusson PB, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5‐10 year follow‐up of the PregMet randomised controlled trial. Lancet Child Adolesc Heal. 2019;3(3):166‐174. doi:10.1016/S2352-4642(18)30385-7
Greger HK, Hanem LGE, Østgård HF, Vanky E. Cognitive function in metformin exposed children, born to mothers with PCOS—follow‐up of an RCT. BMC Pediatr. 2020;20(1):1‐10. doi:10.1186/s12887-020-1960-2